Welcome to our dedicated page for Dexcom SEC filings (Ticker: DXCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DexCom, Inc. (DXCM) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K, annual reports on Form 10-K, and quarterly reports on Form 10-Q when filed. Dexcom is listed on the Nasdaq Stock Market under the symbol DXCM, and its SEC filings offer detailed information on financial performance, governance, and material events related to its glucose biosensing and continuous glucose monitoring (CGM) business.
Recent Form 8-K filings illustrate how Dexcom uses SEC reports to communicate key developments. For example, the company has filed 8-Ks to furnish quarterly financial results, including revenue by geography and product component, and to describe leadership transitions such as the appointment of Jacob S. Leach as President and Chief Executive Officer and the appointment of Dr. Euan Ashley to the Board of Directors. These filings also document changes in board size, committee assignments, and executive roles.
Dexcom’s periodic reports, including 10-K and 10-Q filings when available, typically contain audited financial statements, discussions of sensor and hardware revenue, descriptions of its CGM and biosensing operations, and risk factor disclosures. Investors can also review sections on research and development spending, capital structure, and non-GAAP performance metrics that the company discusses alongside GAAP results in its earnings-related 8-Ks.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand revenue trends, margin commentary, governance updates, and other material items. Users can also monitor items related to director and executive appointments or departures, and other reportable events under Form 8-K. This page is a central resource for analyzing Dexcom’s regulatory history and for tracking how financial and governance information evolves over time.
DexCom (DXCM) Form 144 notice reports a proposed sale of 2,750 common shares through UBS Financial Services on NASDAQ, with an aggregate market value of $220,797.50 and approximately 392,155,265 shares outstanding. The shares were acquired as vested RSUs on 05/19/2022 and payment was recorded the same day. The filer notes an approximate sale date of 08/15/2025. The filing also discloses two prior sales by the same account: 2,750 shares on 06/16/2025 for $228,604.75 and 2,750 shares on 07/15/2025 for $234,216.67. The notice includes standard Rule 144 representations but contains no entered dates or signature data in the remarks section.
DexCom, Inc. (DXCM) – Form 4 insider transaction
EVP & Chief HR Officer Sadie Stern reported the sale of 1,466 common shares on 26-Jun-2025 at an average price of $85.06, generating gross proceeds of roughly $125,000. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted 20-Feb-2025, signalling that timing was automated rather than discretionary.
Following the sale, Stern’s beneficial ownership stands at 108,155 shares, of which 74,450 are unvested RSUs scheduled to vest between 2026 and 2028. The reported sale represents ~1.4% of her post-transaction holdings, leaving her overall exposure to DexCom equity largely intact.
No derivative transactions, option exercises, or additional sales were disclosed, and there is no indication of strategic changes or financial performance data within this filing.
DexCom (NASDAQ: DXCM) Officer Sadie Stern has filed a Form 144 notice indicating a proposed sale of 1,466 shares of common stock with an aggregate market value of $124,697.96. The planned transaction is scheduled for execution on June 26, 2025, through Morgan Stanley Smith Barney LLC.
The shares to be sold were acquired as Restricted Stock from the issuer on November 19, 2023. The filing also discloses Stern's recent trading activity, showing three previous sales in May 2025 totaling 6,184 shares with combined gross proceeds of $526,318.38.
The transaction is being executed under a Rule 10b5-1 trading plan adopted on February 20, 2025. As of the filing date, DexCom has 392,107,501 shares outstanding. The seller has certified no knowledge of material adverse non-public information regarding the company's operations.
FAQ
What is the current stock price of Dexcom (DXCM)?
What is the market cap of Dexcom (DXCM)?
